The New England journal of medicine, 2022-03, Vol.386 (12), p.1132-1142
- Smith, Matthew R
- Hussain, Maha
- Saad, Fred
- Fizazi, Karim
- Sternberg, Cora N
- Crawford, E. David
- Kopyltsov, Evgeny
- Park, Chandler H
- Alekseev, Boris
- Montesa-Pino, Álvaro
- Ye, Dingwei
- Parnis, Francis
- Cruz, Felipe
- Tammela, Teuvo L.J
- Suzuki, Hiroyoshi
- Utriainen, Tapio
- Fu, Cheng
- Uemura, Motohide
- Méndez-Vidal, María J
- Maughan, Benjamin L
- Joensuu, Heikki
- Thiele, Silke
- Li, Rui
- Kuss, Iris
- Tombal, Bertrand
2022
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Smith, Matthew R
- Hussain, Maha
- Saad, Fred
- Fizazi, Karim
- Sternberg, Cora N
- Crawford, E. David
- Kopyltsov, Evgeny
- Park, Chandler H
- Alekseev, Boris
- Montesa-Pino, Álvaro
- Ye, Dingwei
- Parnis, Francis
- Cruz, Felipe
- Tammela, Teuvo L.J
- Suzuki, Hiroyoshi
- Utriainen, Tapio
- Fu, Cheng
- Uemura, Motohide
- Méndez-Vidal, María J
- Maughan, Benjamin L
- Joensuu, Heikki
- Thiele, Silke
- Li, Rui
- Kuss, Iris
- Tombal, Bertrand
- Titel
- Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer
- Ist Teil von
- The New England journal of medicine, 2022-03, Vol.386 (12), p.1132-1142
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2022
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Standard therapy for metastatic, hormone-sensitive prostate cancer is androgen-deprivation therapy, usually with docetaxel. A large, multinational, phase 3 trial assessed the addition of the androgen-receptor blocker darolutamide to standard therapy. At 4 years, survival was higher with darolutamide than with placebo (62.7% vs. 50.4%), with no major differences in the frequency of adverse events.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793, 1533-4406eISSN: 1533-4406DOI: 10.1056/NEJMoa2119115Titel-ID: cdi_proquest_journals_2642408631
- Format
- –
- Schlagworte
- Aged, Aged, 80 and over, Androgen Antagonists - therapeutic use, Androgen Receptor Antagonists - adverse effects, Androgen Receptor Antagonists - therapeutic use, Androgens, Antineoplastic Agents - adverse effects, Antineoplastic Agents - therapeutic use, Cancer therapies, Castration, Docetaxel - adverse effects, Docetaxel - therapeutic use, Drug dosages, Drug Therapy, Combination, Genitourinary Cancer, Hematology, Humans, Kaplan-Meier Estimate, Magnetic resonance imaging, Male, Metastases, Metastasis, Middle Aged, Narcotics, Neoplasm Metastasis - drug therapy, Neutropenia, Neutropenia - chemically induced, Oncology, Pain, Patients, Placebos, Proportional Hazards Models, Prostate cancer, Prostate Disease, Prostate Disease General, Prostatic Neoplasms - drug therapy, Prostatic Neoplasms - mortality, Prostatic Neoplasms - pathology, Prostatic Neoplasms, Castration-Resistant, Pyrazoles - adverse effects, Pyrazoles - therapeutic use, Questionnaires, Statistical analysis, Survival, Treatments in Oncology, Urology